Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ASCO GU 2025

13 - 15 Feb 2025

Moscone West, San Francisco, United States of America

Talazoparib and enzalutamide combination therapy shows significant benefit in...

Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA

Talazoparib and enzalutamide combination therapy shows significant benefit in treating mCRPC ( Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA )

Belzutifan is more efficacious than everolimus in the treatment of metastatic...

Dr Guillermo De Velasco - University Hospital 12 de Octubre, Madrid, Spain

Belzutifan is more efficacious than everolimus in the treatment of metastatic renal cell carcinoma ( Dr Guillermo De Velasco - University Hospital 12 de Octubre, Madrid, Spain )

Mevrometostat and enzalutamide show improved outcomes compared to enzalutamide...

Dr Michael Schweizer - University of Washington Fred Hutch Cancer Center...

Mevrometostat and enzalutamide show improved outcomes compared to enzalutamide alone in mCRPC ( Dr Michael Schweizer - University of Washington Fred Hutch Cancer Center, Seattle, Washington )

Time to metastasis after prostatectomy should not be used as a prognostic...

Dr Nicolas Sayegh - UT Southwestern Medical Center, Dallas, USA

Time to metastasis after prostatectomy should not be used as a prognostic factor for metachronous mHSPC ( Dr Nicolas Sayegh - UT Southwestern Medical Center, Dallas, USA )

Combining chemotherapy with cemiplimab for advanced penile cancer may serve as...

Prof Amit Bahl - University Hospitals Bristol, Bristol, UK

Combining chemotherapy with cemiplimab for advanced penile cancer may serve as a viable first-line treatment option ( Prof Amit Bahl - University Hospitals Bristol, Bristol, UK )

KIM-1 is a good prognostic and predictive biomarker in advanced renal cell...

Dr Wenxin Xu - Dana-Farber Cancer Institute, Boston, USA

KIM-1 is a good prognostic and predictive biomarker in advanced renal cell carcinoma ( Dr Wenxin Xu - Dana-Farber Cancer Institute, Boston, USA )

UGN-102 shows better results after 12 months of treatment for low-grade...

Dr Sandip Prasad - Garden State Urology, Morristown, USA

UGN-102 shows better results after 12 months of treatment for low-grade intermediate-risk NMIBC ( Dr Sandip Prasad - Garden State Urology, Morristown, USA )

Mobile prostate cancer screening clinic can help address barriers to serving...

Dr Masood Moghul - The Royal Marsden Institute of Cancer Research, London, UK

Mobile prostate cancer screening clinic can help address barriers to serving high-risk communities ( Dr Masood Moghul - The Royal Marsden Institute of Cancer Research, London, UK )

177Lu-PSMA-617 with concomitant ARPIs shows is more efficacious than SoC in...

Dr Omid Yazdanpanah - University of California Irvine, Irvine, USA

177Lu-PSMA-617 with concomitant ARPIs shows is more efficacious than SoC in mCRPC ( Dr Omid Yazdanpanah - University of California Irvine, Irvine, USA )

CaboNivo shows sustained long-term benefits for survival and tumour progression...

Prof Camillo Porta - University of Bari, Bari, Italy,

CaboNivo shows sustained long-term benefits for survival and tumour progression as a 1L treatment of aRCC ( Prof Camillo Porta - University of Bari, Bari, Italy, )

HSD3B1 inheritance reduces OS in high-risk nmPC patients on ADT enzalutamide...

Dr Nima Sharifi - University of Miami Miller School of Medicine, Miami, USA

HSD3B1 inheritance reduces OS in high-risk nmPC patients on ADT enzalutamide, abiraterone acetate plus prednisolone ( Dr Nima Sharifi - University of Miami Miller School of Medicine, Miami, USA )

Enfortumab vedotin in combination with pembrolizumab shows improved survival...

Prof Thomas Powles - Barts Cancer Institute, London, England

Enfortumab vedotin in combination with pembrolizumab shows improved survival rates in la/mUC ( Prof Thomas Powles - Barts Cancer Institute, London, England )

ASCO GU 2025: Latest updates in mRCC

Dr Bradley McGregor, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Roberto...

ASCO GU 2025: Latest updates in mRCC ( Dr Bradley McGregor, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Roberto Iacovelli )

More from ecancer